Match tier Listed
Presence Current · Arkansas
Last published 2025
Sources OpenAlex · ORCID
Refreshed 2026-10-08
Eric C. Peterson profile photo

Eric C. Peterson

High Impact

Professor

Also affiliated: Dartmouth College (2021); University of Minnesota (1981); The Royal Melbourne Hospital (2018); Johns Hopkins University (2018); University of Miami (2011–2024); The University of Melbourne (2018); University of California, Irvine (1994–1999); Durham Technical Community College (2016); Johns Hopkins Medicine (2018); Harborview Medical Center (2014); Boca Raton Regional Hospital (2018–2019); Jackson Memorial Hospital (2014–2023); Henry Ford Hospital (2008); Peterson (Norway) (2018–2024); Zimmer Biomet (United States) (1998); University of Miami Hospital (2015–2017); Duke Medical Center (1998–2004); University of Pittsburgh Medical Center (2017–2018); Miami Children's Hospital (2016); Health and Education Research Management and Epidemiologic Services (United States) (2023); Duke University Hospital (1998); Neurological Surgery (2009–2023); AdventHealth (2017); Toronto Metropolitan University (2021); Columbia University (2016); Tokushima University (2021)

Pharmacology & Toxicology, College of Medicine

38 h-index 153 pubs 5,380 cited

  • Humans
  • Female
  • Male
  • Middle Aged
  • Aged
  • Treatment Outcome
  • Retrospective Studies
  • Radial Artery
  • Embolization, Therapeutic
  • Endovascular Procedures
  • Adult
  • Stroke
  • Cerebral Angiography
  • Thrombectomy
  • Aged, 80 and over

Biography and Research Information

OverviewAI-generated summary

Eric C. Peterson's research program focuses on the investigation of acute ischemic stroke, particularly the outcomes associated with endovascular thrombectomy. He has published extensively on this topic, examining factors such as interhospital transfer delays, the role of penumbral imaging, and the impact of general anesthesia on functional outcomes. His work includes meta-analyses of individual patient-level data to synthesize evidence from multiple studies.

Peterson also contributes to the understanding of cerebral aneurysms, studying their biology and physics, including formation, growth, and rupture. His research portfolio extends to other areas, including myeloma relapse and the development of cancer-related entrepreneurial technologies, for which he serves as Co-PI on a grant from the NIH/National Cancer Institute. His scholarship metrics include an h-index of 38, over 153 publications, and more than 5,380 citations, reflecting his designation as a highly cited researcher. He leads a research group and collaborates with several colleagues at the University of Arkansas for Medical Sciences.

Metrics

  • h-index: 38
  • Publications: 153
  • Citations: 5,380

Positions

  • Professor publications 2014–2025
    University of Arkansas for Medical Sciences Pharmacology & Toxicology, College of Medicine Institutional directory
  • University of Miami Health System
    Neurological Surgery ORCID

Selected Publications

  • Case 3: An Uncommon Cause of Respiratory Distress in a Term Newborn (2025)
  • A functional surface display system in Saccharomyces boulardii for protein absorption in simulated intestinal fluids (2025)
    iScience 1 citation DOI OpenAlex
  • Antagonizing the SAMD9 pathway is key to myxoma virus host shut-off and immune evasion (2024)
    bioRxiv (Cold Spring Harbor Laboratory) 1 citation DOI OpenAlex
  • Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2023)
    Frontiers in Pharmacology 4 citations DOI OpenAlex
  • Liquid biopsy based on circulating tumor DNA for lung cancer: A step toward prevention (2023)
    Elsevier eBooks DOI OpenAlex
  • An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics (2023)
    Frontiers in Genetics 6 citations DOI OpenAlex
  • Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2022)
    bioRxiv (Cold Spring Harbor Laboratory) DOI OpenAlex
  • Effect of Antigen Retrieval on Genomic DNA From Immunodissected Samples (2022)
    Journal of Histochemistry & Cytochemistry 4 citations DOI OpenAlex
  • Myxoma virus lacking the host range determinant M062 stimulates cGAS-dependent type 1 interferon response and unique transcriptomic changes in human monocytes/macrophages (2022)
    PLoS Pathogens 15 citations DOI OpenAlex
  • Abstract 5038: Applying reproducible genomic data science methods for the analysis of a rare tumor type (2022)
    Cancer Research 1 citation DOI OpenAlex
  • Methamphetamine‐Induced Proteomic Changes Within the Neuroinflammatory TLR4 Pathway Persist After Long‐Term Self‐Administration in Rats (2022)
    The FASEB Journal DOI OpenAlex
  • Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations (2022)
    Pediatric Blood & Cancer 14 citations DOI OpenAlex
  • Microdissection Methods Utilizing Single-Cell Subtype Analysis and the Impact on Precision Medicine (2022)
    Methods in molecular biology 2 citations DOI OpenAlex
  • Myxoma virus lacking the host range determinant M062 stimulates cGAS-dependent type 1 interferon response and unique transcriptomic changes in human macrophages (2022)
    bioRxiv (Cold Spring Harbor Laboratory) 4 citations DOI OpenAlex
  • NPARS—A Novel Approach to Address Accuracy and Reproducibility in Genomic Data Science (2021)
    Frontiers in Big Data 4 citations DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 1 $300,402 total

NIH Co-PI Sep 2025 - Aug 2030

Cancer and Developing Entrepreneurial Technologies (CADET)

National Cancer Institute $300,402 R25

Grants & Funding

As listed on this researcher's institutional profile. Federal awards with verified records are shown above.

  • Active Immunization for Treating Methamphetamine Abuse NIH/Nat. Inst. on Drug Abuse Co-Investigator
  • Pharmacology and Therapy for MDPV and alpha-PVP Like Drugs of Abuse NIH/Nat. Inst. on Drug Abuse Co-Investigator
  • Antibody-based Therapy for Methamphetamine Abuse NIH/Nat. Inst. on Drug Abuse Co-Investigator
  • Technology for Identification of Epiproteomes in Tissue Samples NIH Co-Investigator
  • Single Chain Antibody Medications for(+)METH Abuse NIH Principal Investigator
  • Antibody Gene Therapy for Methamphetamine Abuse NIH Principal Investigator
  • Antibody-nanoparticle conjugates for the treatment of methamphetamine abuse NIH Principal Investigator
  • Arkansas Collaborative for Technological and Innovative Venture Equality (ACTIVE) US Department of Commerce Principal Investigator

Collaboration Network

155 Collaborators 40 Institutions 6 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics